HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Chardan Capital reduced their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Performance

NASDAQ FEMY opened at $1.04 on Wednesday. The company’s fifty day moving average is $1.14 and its two-hundred day moving average is $1.13. The firm has a market capitalization of $23.81 million, a price-to-earnings ratio of -1.28 and a beta of -2.83. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million. Equities research analysts forecast that Femasys will post -0.84 EPS for the current year.

Institutional Investors Weigh In On Femasys

Institutional investors have recently added to or reduced their stakes in the stock. CM Management LLC boosted its stake in Femasys by 6.3% in the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after buying an additional 25,000 shares in the last quarter. Aljian Capital Management LLC bought a new position in shares of Femasys during the third quarter valued at $27,000. XTX Topco Ltd boosted its stake in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.